![Christopher Chai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Chai
Direktor/Vorstandsmitglied bei
SURROZEN, INC.
Vermögen: 51 994 $ am 31.07.2026
Profil
Christopher Y.
Chai is currently an Independent Director at Surrozen, Inc. since 2021, a Director at Surrozen Operating, Inc. since 2021, a Venture Partner at GSK Equity Investments Ltd. since 2021, and a Venture Partner at SR One Capital Management LP since 2021.
Former roles include Director at Transcriptx, Inc. from 2016 to 2020, Chief Financial & Accounting Officer at Principia Biopharma, Inc. from 2013 to 2020, Treasurer, VP & Head-Investor Relations at CV Therapeutics, Inc. in 2006, CFO, Senior VP & Investor Relations Contact at MAP Pharmaceuticals LLC from 2011 to 2013, and Principal at JPMorgan Chase & Co. Education includes undergraduate studies at Cornell University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SURROZEN INC 0.02% | 13.05.2026 | 2’341 ( 0.02% ) | 51 994 $ | 31.07.2026 |
Aktive Positionen von Christopher Chai
| Unternehmen | Position | Beginn |
|---|---|---|
| SURROZEN, INC. | Direktor/Vorstandsmitglied | 01.04.2021 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 11.02.2021 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Direktor/Vorstandsmitglied | 06.05.2021 |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 01.01.2021 |
Ehemalige bekannte Positionen von Christopher Chai
| Unternehmen | Position | Ende |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Finanzdirektor/CFO | 28.09.2020 |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Direktor/Vorstandsmitglied | 01.01.2020 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Finanzdirektor/CFO | 01.01.2013 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Public Communications Contact | 01.01.2006 |
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | - |
Ausbildung von Christopher Chai
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
73
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule drugs | Health Technology |
JPMorgan Chase & Co.
 JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a R&D driven and AI-powered biopharma company | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Surrozen, Inc.
 Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
